Brief: Eton Pharmaceuticals Announces FDA Acceptance Of New Drug Application For Et-600
08/07/2025 12:25
July 8 (Reuters) - Eton Pharmaceuticals Inc ETON.O: ETON PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ET-600 (DESMOPRESSIN ORAL SOLUTION) ETON PHARMACEUTICALS INC - NDA TARGET ACTION DATE SET FOR FEBRUARY 25, 2026 ETON PHARMACEUTICALS INC - ET-600 HAS PATENT PROTECTION THROUGH 2044 ETON PHARMACEUTICALS INC - ET-600 ANTICIPATED TO LAUNCH IN Q1 2026 Source text: ID:nGNX1gggCm Further company coverage: ETON.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eton Pharmaceuticals
See all newsBrief: Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing
Aquestive rises on US licensing deal for seizure drug with Eton Pharma
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer